Antibody landscapes after influenza virus infection or vaccination
暂无分享,去创建一个
C. A. Russell | Judith M. Fonville | P. Horby | H. Wertheim | M. Ventresca | I. Barr | M. Aban | A. Osterhaus | L. Xue | A. Hurt | L. Katzelnick | D. Labonte | Derek J. Smith | J. D. de Jong | G. Rimmelzwaan | R. Fouchier | C. Russell | J. M. Fonville | T. Jones | Q. M. Le | J. C. Jong | W. Beyer | A. Fox | M. Ventresca | A. Mosterín | E. Skepner | A. Palache | N. Masurel | Sarah L James | J. C. de Jong | D. J. Smith | T. C. Jones | G. F. Rimmelzwaan | A. D. M. E. Osterhaus | R. A. M. Fouchier | W. E. P. Beyer | N. Masurel | S. H. Wilks | S. L. James | A. Fox | M. Aban | L. Xue | Le N. M. H. | Pham Q. T. | Tran N. D. | Y. Wong | A. Mosterin | L. C. Katzelnick | D. Labonte | Le T. T. | G. van der Net | E. Skepner | T. D. Kaplan | A. Palache | Le Q. M. | Nguyen T. H. | H. F. L. Wertheim | A. C. Hurt | I. G. Barr | P. W. Horby | S. James | G. Net | S. Wilks | W. E. Beyer | A. Hurt | G. van der Net | D. Smith | T. H. Nguyen | Y. Wong | Q. T. Pham | N. Le | N. Tran | Ana Mosterín | David Labonte | T. T. Le | Malet Aban | W. P. Beyer
[1] F. M. Davenport,et al. A SEROLOGIC RECAPITULATION OF PAST EXPERIENCES WITH INFLUENZA A; ANTIBODY RESPONSE TO MONOVALENT VACCINE , 1956, The Journal of experimental medicine.
[2] Florian Krammer,et al. Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis , 2013, Science Translational Medicine.
[3] René Ecochard,et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model , 2010, BMC medical research methodology.
[4] R. Webster,et al. DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.
[5] J. Piercy,et al. Immunogenicity and protective efficacy of influenza vaccination. , 2004, Virus research.
[6] R. Webster,et al. Disquisitions of Original Antigenic Sin. I. Evidence in man. , 1966, The Journal of experimental medicine.
[7] D. Burke,et al. Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution , 2013, Science.
[8] T. Francis,et al. Epidemiology of influenza; comparative serological observations in England and the United States. , 1955, Lancet.
[9] P. Horby,et al. Influenza Infection Rates, Measurement Errors and the Interpretation of Paired Serology , 2012, PLoS pathogens.
[10] Yan Li,et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. , 2009, The Journal of infectious diseases.
[11] F. Horsfall,et al. NEUTRALIZING ANTIBODIES IN HUMAN SERUM AFTER INFLUENZA A , 1941, The Journal of experimental medicine.
[12] P. Horby,et al. Contribution The Epidemiology of Interpandemic and Pandemic Influenza in Vietnam , 2007 – 2010 The Ha Nam Household Cohort Study I , 2012 .
[13] Patrick C. Wilson,et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.
[14] M. Sherman,et al. A Preliminary Report , 1953 .
[15] L. A. Stone,et al. Computer Aided Design of Experiments , 1969 .
[16] R. Compans,et al. Original Antigenic Sin Responses to Influenza Viruses1 , 2009, The Journal of Immunology.
[17] G. Lüchters,et al. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.
[18] D. Sommers,et al. A longitudinal analysis , 1992 .
[19] W G Laver,et al. Molecular mechanisms of variation in influenza viruses , 1982, Nature.
[20] R. Greenlee,et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. , 2009, The Journal of infectious diseases.
[21] Recommended composition of influenza virus vaccines for use in the 2010 influenza season (southern hemisphere winter). , 2009, Releve epidemiologique hebdomadaire.
[22] M. Meltzer,et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.
[23] Keyao Pan. Understanding Original Antigenic Sin in Influenza with a Dynamical System , 2011, PloS one.
[24] K. Subbarao,et al. Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus , 2014, Clinical and Vaccine Immunology.
[25] A. Monto. Epidemiology of influenza. , 2008, Vaccine.
[26] T. Francis,et al. Studies of antibodies to strains of influenza virus in persons of different ages in sera collected in a postepidemic period. , 1955, Journal of immunology.
[27] Gavin J. D. Smith,et al. Evidence for Antigenic Seniority in Influenza A (H3N2) Antibody Responses in Southern China , 2012, PLoS pathogens.
[28] M. Diamond,et al. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants , 2011, The Journal of experimental medicine.
[29] W. Fitch,et al. Positive Darwinian evolution in human influenza A viruses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[30] Thomas Francis,et al. EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.
[31] M. Ventresca,et al. Prevalence of Antibodies against Seasonal Influenza A and B Viruses in Children in Netherlands , 2011, Clinical and Vaccine Immunology.
[32] A. Lapedes,et al. Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.
[33] Keiji Fukuda,et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. , 2010, Vaccine.
[34] A S Perelson,et al. Variable efficacy of repeated annual influenza vaccination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[35] G. K. Hirst. THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION , 1942, The Journal of experimental medicine.
[36] T. Francis,et al. Experience with Vaccination Against Influenza in the Spring of 1947: A Preliminary Report. , 1947, American journal of public health and the nation's health.